CO2022014343A2 - Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización - Google Patents

Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización

Info

Publication number
CO2022014343A2
CO2022014343A2 CONC2022/0014343A CO2022014343A CO2022014343A2 CO 2022014343 A2 CO2022014343 A2 CO 2022014343A2 CO 2022014343 A CO2022014343 A CO 2022014343A CO 2022014343 A2 CO2022014343 A2 CO 2022014343A2
Authority
CO
Colombia
Prior art keywords
methods
reperfusion injury
hemorrhage
compositions
thrombolytic
Prior art date
Application number
CONC2022/0014343A
Other languages
English (en)
Spanish (es)
Inventor
Byoung Joo Gwag
Chun San An
Jing Yu Jin
Sung Ig Cho
Fangmeng Zhu
Xinliang Xu
Weiqiang Zhan
Fuxin Liu
Soon-Mi Won
Original Assignee
Gnt Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gnt Pharma Co Ltd filed Critical Gnt Pharma Co Ltd
Publication of CO2022014343A2 publication Critical patent/CO2022014343A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CONC2022/0014343A 2020-03-11 2022-10-07 Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización CO2022014343A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988187P 2020-03-11 2020-03-11
PCT/IB2021/000136 WO2021181159A1 (en) 2020-03-11 2021-03-10 Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Publications (1)

Publication Number Publication Date
CO2022014343A2 true CO2022014343A2 (es) 2023-02-16

Family

ID=77665492

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014343A CO2022014343A2 (es) 2020-03-11 2022-10-07 Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización

Country Status (12)

Country Link
US (3) US11826329B2 (https=)
EP (1) EP4117648A4 (https=)
JP (1) JP2023517566A (https=)
KR (1) KR20230010187A (https=)
CN (1) CN115515573A (https=)
AU (1) AU2021233206A1 (https=)
BR (1) BR112022018136A2 (https=)
CA (1) CA3174709A1 (https=)
CO (1) CO2022014343A2 (https=)
IL (2) IL296288B2 (https=)
MX (2) MX2022011214A (https=)
WO (1) WO2021181159A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy
CN113995723B (zh) * 2020-07-27 2025-02-18 浙江普洛家园药业有限公司 一种索法地尔冻干粉针剂的制备方法及其产品和用途
KR20240142433A (ko) * 2021-12-28 2024-09-30 주식회사 지엔티파마 폐 장애를 치료하기 위한 조성물 및 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1309703C (zh) * 2002-06-19 2007-04-11 纽若泰克有限公司 四氟苄基衍生物及含有其成分的用于治疗和预防中枢神经系统的急慢性神经变性疾病的药物组合物
KR100522188B1 (ko) * 2003-01-20 2005-10-18 주식회사 뉴로테크 뉴로트로핀에 의해 유도되는 세포괴사 억제 방법
WO2006126825A1 (en) 2005-05-23 2006-11-30 Choongwae Pharma Corporation Composition comprising tetrafluorobenzyl derivatives or salts of thereof for injection
CN101180263B (zh) 2005-05-25 2011-11-02 株式会社中外制药 取代四氟苄基苯胺化合物及其药学可接受的盐的制备方法
KR101523345B1 (ko) 2008-04-28 2015-05-28 주식회사 지엔티파마 재관류 손상의 치료 또는 예방용 약학 조성물
CN102617383A (zh) 2012-03-20 2012-08-01 横店集团家园化工有限公司 索法地尔晶型、制备方法及包含索法地尔晶体的无菌粉末
JP2018502894A (ja) 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
AU2021233206A1 (en) 2020-03-11 2022-10-06 Gnt Pharma Co., Ltd. Compositions and methods for treating reperfusion injury or hemorrhage after recanalization therapy

Also Published As

Publication number Publication date
EP4117648A1 (en) 2023-01-18
EP4117648A4 (en) 2024-05-29
US12433861B2 (en) 2025-10-07
KR20230010187A (ko) 2023-01-18
IL296288B1 (en) 2024-02-01
US20260027076A1 (en) 2026-01-29
US20230390231A1 (en) 2023-12-07
JP2023517566A (ja) 2023-04-26
US20210283080A1 (en) 2021-09-16
IL309923A (en) 2024-03-01
IL296288A (en) 2022-11-01
US11826329B2 (en) 2023-11-28
WO2021181159A1 (en) 2021-09-16
BR112022018136A2 (pt) 2022-10-25
MX2022011214A (es) 2022-10-07
AU2021233206A1 (en) 2022-10-06
CN115515573A (zh) 2022-12-23
IL296288B2 (en) 2024-06-01
MX2025012439A (es) 2025-11-03
CA3174709A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
CO2022014343A2 (es) Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización
CO2022012975A2 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CR20220281A (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CO2022002842A2 (es) Degradadores bifuncionales de brd9 y sus métodos de uso
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
PE20242299A1 (es) Composiciones agonistas de gip/glp1
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
GT200000184A (es) Composiciones para facilitar el crecimiento de la piel y metodos y articulos que la emplean.
MX394098B (es) Compuestos inhibidores de ask1 y usos de los mismos
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CO2022005999A2 (es) Inhibidores del factor d del complemento para administración oral
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa
AR131735A1 (es) Agentes terapéuticos
CL2021000627A1 (es) Composiciones farmacéuticas adecuadas para liberación articular y su uso en el tratamiento del dolor articular
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CL2019003467A1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
CO2019002616A2 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
AR131503A1 (es) Antagonistas de hpk1 espirocíclicos y usos de los mismos
CO2024005025A2 (es) Composiciones líquidas orales de enzalutamida
AR129578A1 (es) MODULADORES DE LA ACTIVIDAD DE TNF-a
ECSP23043458A (es) Inmunocitoquina para activar el receptor IL-10Ra humano y su uso